Advertisement

Failure to Demonstrate Plasma Hormone Abnormalities in Women with Operable Breast Cancer

  • I. Ricciardi
  • S. De Placido
  • C. Pagliarulo
  • G. Delrio
  • F. Citarella
  • L. De Sio
  • M. D. Istria
  • S. Fasano
  • G. Petrella
  • A. Contegiacomo
  • R. V. Iaffaioli
  • A. R. Bianco

Abstract

The endocrine profile of patients with breast cancer has been the object of extensive studies during the past several years. Abnormal secretion of a variety of hormones has been described on different occasions in patients with breast cancer (Gambrell, 1982; Henderson et al., 1982; Kirschner et al., 1982; Kwa and Wang, 1977; Ohgo et al., 1976), and has been considered a possible risk factor. However, conclusive evidence has not yet been presented to show that the cancer patients are significantly different in endogenous hormone profiles from their healthy counterparts. The main purpose of the present study was to critically reevaluate this controversial issue and possibly identify hormonal changes in a large population of patients with operable breast cancer not present in a comparable population of normal healthy women.

Keywords

Breast Cancer Breast Cancer Patient Luteinizing Hormone Follicle Stimulate Hormone Thyroid Stimulate Hormone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bruning, P.F., Bonfrer, H., Dejong-Bakker, M., Hart, A. A. M., and Kwa, H. G., 1983, Prolactin and steroid hormones in premenopausal women at risk for breast cancer, Proc. 3rd EORTC Breast Cancer Working Conf., Amsterdam, April 27–29.Google Scholar
  2. Cole, P., Cramer, D., Yen, S., Pattenbarger, R., McMahon, B., and Brown, J., 1978, Estrogen profiles of premenopausal women with breast cancer, Cancer Res., 38: 745.PubMedGoogle Scholar
  3. England, P.C., Skinner, L. G., Cottrel, K. M., and Seilwood, R.A., 1974, Serum oestradiol-17 in women with benign and malignant breast disease, Brit. J. Cancer, 30: 571.PubMedCrossRefGoogle Scholar
  4. Gambrell, R. D., 1982, Role of hormones in the etiology and prevention of endometrial and breast cancer, Acta Obstet. Gynaecol.Scand. (suppl.), 106: 37.CrossRefGoogle Scholar
  5. Grattarola, R., Secreto, G., and Recchione, C., 1975, Androgens in breast cancer. III. Breast cancer recurrences years after mastectomy and increased androgen activity, Am. J. Obst. Gynecol., 118: 173.Google Scholar
  6. Henderson, B. E., Gerkins, V., Rosario, I., Casagrande, J., and Pike, M. C., 1975, Elevated serum levels of estrogen and prolactin in daughters of patients with breast cancer, N. Engl. J. Med., 293: 790.PubMedCrossRefGoogle Scholar
  7. Henderson, B. E., Ross, R. K., and Pike, M. C., 1982, Endogenous hormones as a major factor in human breast cancer, Cancer Res. (suppl. 8 ), 42: 3232.Google Scholar
  8. Horwitz, K. B., McGuire, W. L., Pearson, O. H., and Segaloff, A., 1975, Predicting response to endocrine therapy in human breast cancer. A hypothesis. Science, 189: 726.Google Scholar
  9. Kirschner, M. A., 1977, The role of hormones in the etiology of human breast cancer, Cancer, 39: 27–36.CrossRefGoogle Scholar
  10. Kirschner, M. A., Schneider, G., and Ertel, N. H., 1982, Obesity, androgens, estrogens and cancer risk, Cancer Res., (suppl. 8 ), 42: 3281.Google Scholar
  11. Kwa, H. G., and Wang, D. Y., 1977, An abnormal luteal-phase evening peak of plasma prolactin in women with a family history of breast cancer, Int. J. Cancer, 20: 12.PubMedCrossRefGoogle Scholar
  12. Malarkey, W. B., Schroeder, L. L., Stevens, V. C., James, A. G., and Lanese, R. R., 1977, Twenty-four hour preoperative endocrine profiles in women with benign and malignant breast disease, Cancer Res., 37: 46–55.Google Scholar
  13. Malarkey, W. B., Schroeder, L. L., Stevens, V. C., James, A. G., and Lanese, R. R., 1977, Disordered noctural prolactin regulation in women with breast cancer, Cancer Res., 37: 4650.PubMedGoogle Scholar
  14. McFayden, W. H., Prescott, I. J., Goom, G. V., Forrest, A. P. M., Golden, M. P., Fahmy, D. R., and Griffiths, K., 1976, Circulating hormone concentrations in women with breast cancer, Lancet, 7: 1100.CrossRefGoogle Scholar
  15. McGuire, W. R., Carbone, P. P., Seans, M. E., and Escher, G. C., 1975, Estrogen receptor in human breast cancer. An overview, in:“Estrogen receptors in human breast cancer”, W.L. Mc Guire, P. P. Carbone, E. P. Wollmer, eds., Raven Press, New York, N. Y.Google Scholar
  16. Ohgo, S., Kato, Y., Chihara, K., and Imura, H., 1976, Plasma prolactin responses to thyrotropin releasing hormone in patients with breast cancer, Cancer, 37: 1412.PubMedCrossRefGoogle Scholar
  17. Porter, J. C., 1974, Hormonal regulation of breast development and activity, J. Invest. Dermatol., 63: 85.PubMedCrossRefGoogle Scholar
  18. Sheth, N. A., Ranadive, K. J., Suraiva, J. N., and Sheth, A. R., 1975, Circulating levels of prolactin in human breast cancer, Brit. J. Cancer, 32: 160.PubMedCrossRefGoogle Scholar
  19. Sherman, B. M., and Korenman, S. G.,1974, Inadeguate corpus luteum function. A pathophysiological interpretation of human breast cancer epidemiology, Cancer, 33: 1306.Google Scholar
  20. Smethutst, M., Alexander, K., and Williams, D. C., 1975, Plasma progestrerone levels in postmenopausal women with breast cancer. IRCS Medical Science. Cancer, endocrine system, metabolism and nutrition, Obstet. Gynecol., 3: 89.Google Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • I. Ricciardi
    • 2
  • S. De Placido
    • 1
  • C. Pagliarulo
    • 1
  • G. Delrio
    • 2
  • F. Citarella
    • 2
  • L. De Sio
    • 1
  • M. D. Istria
    • 2
  • S. Fasano
    • 2
  • G. Petrella
    • 1
  • A. Contegiacomo
    • 1
  • R. V. Iaffaioli
    • 1
  • A. R. Bianco
    • 1
  1. 1.Istituto di Oncologia, II Facoltà di MedicinaUniversità di NapoliItaly
  2. 2.Istituto di Biologia Generale Facoltà di MedicinaUniversità di NapoliItaly

Personalised recommendations